Author

J. M. Warrington

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3 Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Research Focus:drug response / drug discovery· 4 Approach:experimental assay· 3 Assay:proteomics· 3 Assay:bulk RNA-seq· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

J. H. Landmann· 2 shared M. E. Selli· 2 shared M. Slade· 2 shared N. Singh· 2 shared P. J. Buckhaults· 2 shared T.-C. Chang· 2 shared Y.-S. Hsu· 2 shared A. Farrel· 1 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

J. H. Landmann

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Rational protein engineering to enhance MHC-independent T cell receptors

J. Chang, J. H. Landmann, T.-C. Chang, Y. Tenzin, J. M. Warrington, M. E. Selli, J. Ritchey, Y.-S. Hsu, M. Slade, D. K. Gupta, J. F. DiPersio, N. Singh

The paper designs MHC-independent T cell receptors (miTCRs) to enhance cancer immunotherapy by improving receptor stability and function through structural modeling and iterative sequence modifications.

bioRxiv · Feb 22, 2024Immunology

Costimulatory domains direct distinct fates of CAR-driven T cell dysfunction

M. E. Selli, J. H. Landmann, M. Terekhova, J. Lattin, A. Heard, Y.-S. Hsu, T.-C. Chang, J. M. Warrington, H. Ha, N. Kingston, G. Hogg, M. Slade, M. M. Berrien-Elliot, M. Foster, S. Kersting-Schadek, , N. Singh

This study identifies that chronic activation of 41BB-based CARs leads to a novel T cell dysfunction state, distinct from exhaustion, which can be mitigated by disrupting FOXO3.

bioRxiv · Jan 26, 2023 · PreprintImmunology

TP53 knockout in MCF7 breast cancer cells induces sensitivity to fluoropyrimidine drugs.

J. M. Warrington, S. Mehta, V. F. Moy, J. Patel, C. Liu, A. Rago, C. McTighe, I. Delgado, C. Banister, W. Gmeiner, P. J. Buckhaults

This study shows TP53 knockout in breast cancer cells increases sensitivity to fluoropyrimidine drugs like F10, with DNA incorporation as a key mechanism.

bioRxiv · Feb 10, 2022 · PreprintCancer Biology

Store Independent Ca2+ Entry Regulates the DNA Damage Response in Breast Cancer Cells

M. R. Makena, M. Ko, A. X. Mekile, D. K. Dang, J. M. Warrington, P. J. Buckhaults, C. Talbot, R. Rao

This study identifies SPCA2 as a driver of chemotherapy resistance in ER+/p53WT breast cancer by suppressing the DNA damage response through store-independent Ca2+ entry.

bioRxiv · Apr 6, 2020 · PreprintCancer Biology

A SARS-CoV-2 Vaccination Strategy Focused on Population-Scale Immunity

M. Yarmarkovich, J. M. Warrington, A. Farrel, J. M. Maris

This paper proposes a SARS-CoV-2 vaccination strategy targeting conserved viral regions and MHC-presented epitopes to induce broad immunity.

bioRxiv · Mar 31, 2020Immunology